InnoCore specializes in formulation, process development and manufacturing of long acting and minimally invasive injectable drug delivery products. We are a target-driven and cost-efficient organization committed to delivering products and services that offer added value to our partners and improve the quality of life of patients. Flexibility, compliance with the highest international quality standards and a true belief in the value of collaborative partnerships are the key elements of the InnoCore approach. InnoCore is a privately owned company and is based in The Netherlands.

 

Mission

 

Science delivering tomorrow's medicine

 

 

 

InnoCore is dedicated to develop minimally invasive and long-acting injectable polymer based depot formulation products for precise delivery of small molecules, peptides and protein therapeutics as to contribute to enhanced patient care.

 

History

  • 15-20  feasibility projects ongoing; of which > 3 in cGMP-stage in 2019/2020

  • Gates Foundation supported consortium on microneedle contraceptive

  • InnoCore renewed the GMP certificate including laboratory authorization converted to manufacturer’s authorization

  • InnoCore is offering InGell Technologies as a service

  • Winner Enterpreneurs Award Groningen

  • InnoCore signs an Exclusive License with Allergan on Ophthalmology.

     

  • CE Mark for SynBiosys containing product with Orbus Neich. 

  • InnoCore established a License in the field of device coatings with its US partner Surmodics Inc.

  • Foundation of InnoCore

We use cookies for analyzing visitors behavior.